| Drug Name | Beovu (brolucizumab) |
|---|---|
| Drug Class |
Immunosuppressant
|
| Risk minimization type |
patient guide
|
| Specialty (Theraputic area) |
Ophthalmology
|
| Risk |
- Visual impairment due to diabetic macular edema (DME) - Emerging Safety Issue increased incidence of Intraocular Inflammation (IOI) and related adverse events - important safety information about using the Beovu |
| patient guide |
|
| Dear Healthcare provider letter DHPC |
|